secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001213900-26-018396
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio to host Feb 26 webinar on new CORDStrom Phase III data for RDEB
--------------------------------------------------------------------------

- Webinar on February 26, 2026 at 1:00 PM ET to present new MissionEB Phase III data for CORDStrom in RDEB.
- Focus: systemic disease-modifying therapy beyond topical care, including EBDASI scores, weight gain, pain/itch reduction, and quality of life.
- Featured speakers: Dr. Anna Martinez (Principal Investigator) and CSO Prof. Mark Lowdell.
- CORDStrom is a patented allogeneic hucMSC cell medicine positioned for inflammatory/autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026018396/0001213900-26-018396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026018396/ea0277663-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-018396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer